Our technology is currently being utilised to highlight our system’s versatility and potential to become the next generation’s immunohistochemistry (IHC) detection system in tissue diagnostics. Our involvement in these studies aims to showcase the range of different applications our technology can be used for. Each pilot study contributes to improving our understanding of the capability and flexibility of our technology, while also exploring new opportunities and applications in the field.
International pilot study in collaboration with a research group at University Hospitals Coventry and Warwickshire in the United Kingdom
Purpose:
The study focused on detecting immunocomplex and complement deposition in renal biopsies using Lumito’s technology.
Results:
The results will be presented in June at Liverpool Congress Pathology 2023 through a poster presentation.
Collaboration with a research group at Umeå University in Sweden
Purpose:
The study explored the capacity of Lumito’s technology when quantifying signals compared to traditional DAB staining.
Results:
The study proved that Lumito’s technology offers more precise measurement results compared to traditional DAB staining, which saturates quickly and decreases the possibility of correct quantification. The research group in Umeå wrote an article about the study published in Cancer Immunology Research. See a presentation of the results here.
Contact us if you’re interested in using our technology in your research
We have telephone hours on weekdays between 08:00 and 14:30. Closed for lunch 12-13.
Phone: +46(0)10-204 00 15
Mail: info@lumito.se
Lumito AB (publ)
Mårtenstorget 5, 223 51, Lund